Core Insights - Cytokinetics is set to report its third quarter results on November 5, 2025, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM to discuss financial results and business updates [1][2] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [3] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, after positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) [3] - Aficamten is also being evaluated in additional clinical trials for both obstructive and non-obstructive HCM [3] - Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator for heart failure with severely reduced ejection fraction (HFrEF), and ulacamten, a cardiac myosin inhibitor for heart failure with preserved ejection fraction (HFpEF) [3] - The company is also working on CK-089, a fast skeletal muscle troponin activator, which may have therapeutic applications for specific muscular dystrophies and other conditions affecting skeletal muscle function [3]

Core Insights - Cytokinetics, Incorporated is facing a securities fraud class action lawsuit due to alleged misleading statements regarding drug development timelines [1][3][6] - The lawsuit claims that the company failed to disclose a Risk Evaluation and Mitigation Strategy (REMS) in their New Drug Application (NDA), leading to delays in FDA approval [2][3] - Financially, Cytokinetics shows a negative price-to-earnings (P/E) ratio of -11.38 and a high price-to-sales ratio of 80.64, indicating challenges in profitability and valuation [4][5][6] Legal Issues - The class action lawsuit is open to investors who suffered losses from misleading statements made between December 27, 2023, and May 6, 2025 [3] - Investors have until November 17, 2025, to join the lawsuit [3] Financial Performance - The company has a current ratio of 6.76, suggesting a strong ability to cover short-term liabilities [5][6] - However, the negative debt-to-equity ratio of -2.33 indicates that liabilities exceed equity, highlighting financial risks [5]

Core Insights - Cytokinetics, Incorporated is focused on developing muscle biology-driven treatments for diseases and has received an "Overweight" rating from Cantor Fitzgerald, indicating confidence in the stock's potential [1][5] - The company granted stock options and restricted stock units (RSUs) to 83 new employees, with RSUs vesting over three years, aligning employee interests with shareholders [2][5] - The stock price of Cytokinetics is currently $59.35, reflecting a 1.56% increase, indicating positive market sentiment [3][5] Company Performance - The stock options have an exercise price of $62.80, matching the closing price on the grant date, which is part of the company's strategy to incentivize new employees [3] - The stock has fluctuated between $58.44 and $60 on the current trading day, with a 52-week high of $63.86 and a low of $29.31, showcasing its volatility [4] - Cytokinetics has a market capitalization of approximately $7.1 billion, highlighting its significant presence in the biopharmaceutical sector [4]

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by alleged securities fraud between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made materially false statements regarding the expected approval timeline for the NDA for aficamten, claiming approval from the FDA in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - The complaint highlights that the company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Cytokinetics during the relevant timeframe have until November 17, 2025, to request the Court to appoint them as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by alleged securities fraud between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made materially false statements regarding the NDA submission timeline and FDA approval expectations, claiming approval in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - The complaint highlights that the company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. Group 2: Impact on Investors - On May 6, 2025, it was revealed during an earnings call that Cytokinetics had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. - As a result of the misleading statements, investors purchased Cytokinetics' common stock at inflated prices and suffered significant losses when the truth was disclosed [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until November 17, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging securities fraud and unlawful business practices related to the company's New Drug Application for aficamten [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Cytokinetics and certain officers or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until November 17, 2025, to request to be appointed as Lead Plaintiff if they purchased Cytokinetics securities during the Class Period [2]. Group 2: FDA Interaction and Stock Impact - On March 10, 2025, Cytokinetics disclosed that the FDA would not convene an advisory committee meeting for aficamten's NDA [4]. - The FDA extended the action date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the need for a Risk Evaluation and Mitigation Strategy (REMS) that was not included in the original NDA [4]. - Following the news, Cytokinetics' stock price fell by $5.57 per share (12.98%) to close at $37.35 on May 2, 2025 [5]. - On May 6, 2025, CEO Robert I. Blum acknowledged that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS [5]. - After this acknowledgment, the stock price fell by $2.70 per share (7.36%) to close at $33.97 on May 6, 2025 [6].

Accessibility StatementSkip Navigation NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+Newsrooms &Influen ...

Core Points - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock from December 27, 2023, to May 6, 2025, about the lead plaintiff deadline on November 17, 2025 [1] - Investors who purchased Cytokinetics stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3] Company Details - The lawsuit alleges that Cytokinetics made false or misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically claiming expected FDA approval in the second half of 2025 based on a September 26, 2025, Prescription Drug User Fee Act (PDUFA) date [5] - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [5] Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [4]

Core Points - A class action securities lawsuit has been filed against Cytokinetics, Incorporated for alleged securities fraud affecting investors between December 27, 2023, and May 6, 2025 [1][2] - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, particularly concerning the expected FDA approval timeline [2] - The company failed to disclose significant risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) in its NDA submission, which could delay the regulatory process [2] Case Details - Defendants allegedly misrepresented the timeline for FDA approval, stating it would occur in the second half of 2025 based on a September 26, 2025 PDUFA date [2] - During an earnings call on May 6, 2025, it was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2] - As a result of these misleading statements, investors purchased Cytokinetics' common stock at inflated prices and incurred significant losses when the truth was disclosed [2] Next Steps - Investors who suffered losses in Cytokinetics during the specified timeframe have until November 17, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 17, 2025 [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries in previous years [4]. Group 3: Case Specifics - The lawsuit alleges that Cytokinetics made false or misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5]. - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process, leading to investor damages when the true information became public [5].